Postmarketing Hepatic Monitoring for Pazopanib Using Observational Databases
Observational
Observational Model: Cohort, Time Perspective: Retrospective
Prescriber compliance with pazopanib label guidelines for liver monitoring
Prescriber compliance with pazopanib label guidelines for liver monitoring
Over four years of treatment with pazopanib
Yes
GSK Clinical Trials
Study Director
GlaxoSmithKline
United States: No Health Authority
114430
NCT01449825
December 2010
December 2014
Name | Location |
---|